1,660
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Analysis of clinical characteristics and prognostic factors associated with EBV-associated HLH in children

, , , , , & show all

References

  • Al-Samkari H, Berliner N. Hemophagocytic lymphohistiocytosis. Annu Rev Pathol Mech Dis. 2018;13:1.1–1.23.
  • Zaher K, Otrock, Daver N, et al. Diagnostic challenges of hemophagocytic lymphohistiocytosis. Clin Lymphoma Myeloma and Leuk. 2017;17:105–110.
  • Henter JI, Horne AC, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–131.
  • Imashuku S, Teramura T, Tauchi H, et al. Longitudinal follow up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica. 2004;89(2):183–188.
  • Kogawa K, Sato H, Asano T, et al. Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: report of the Japan histiocytosis study group. Pediatr Blood Cancer. 2014;61(7):1257–1262.
  • Allen CE, Yu X, Kozinetz CA, et al. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50:1227–1235.
  • Fujiwara F, Imashuku S. Hypercytokinemia in hemophagocytic syndrome. Am J Pediatr Hematol Oncol. 1993;15(1):92–98.
  • Khare N, Jinkala SR, Kanungo S. Performance of HScore in reactive hemophagocytic lymphohistiocytosis. Indian J Hematol Blood Transfus. 2021;37(2):256–263.
  • Smits BM, van Montfrans J, Merrill SA, et al. A minimal parameter set facilitating early decision-making in the diagnosis of hemophagocytic lymphohistiocytosis. J Clin Immunol. 2021;41(6):1219–1228.
  • Zhao XX, Lian HY, Zhang L, et al. Significance of serum ferritin level in hemophagocytic lymphohistiocytosis diagnosis. Int J Lab Hematol. 2019;41(4):503–508.
  • Shi J, Chu C, Yu M, et al. Clinical warning of hemophagocytic syndrome caused by Epstein-Barr virus. Ital J Pediatr. 2021;47(1):3.
  • Nixon A, Roddick E, Moore K, et al. A qualitative investigation into the impact of hemophagocytic lymphohistiocytosis on children and their caregivers. Orphanet J Rare Dis. 2021;16(1):205. DOI:10.1186/s13023-021-01832-2. PMID: 33957935; PMCID: PMC8101208.
  • Merli P, Algeri M, Gaspari S, et al. Novel therapeutic approaches to familial HLH (Emapalumab in FHL). Front Immunol. 2020;11:608492.
  • Chang BS F, Morales CE A, et al. Secondary hemophagocytic lymphohistiocytosis in a young hispanic adult. Cureus. 2021;13(2):e13084.
  • Puliyel MM, Rose W, Kumar S, et al. Prolonged neurologic course of familial hemophagocytic lymphohistiocytosis. Pediatr Neurol. 2009;41:207–216.
  • Clementi R, Emmi L, Maccario R, et al. Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood. 2002;100:2266–2274.
  • Kim WY, Montes-Mojarro IA, Fend F, et al. Epstein-Barr virus-associated T and NK-cell lymphoproliferative diseases. Front Pediatr. 2019 Mar 15;7:71. doi:10.3389/fped.2019.00071.
  • Popko K, Górska E, Wołowiec M, et al. Disturbances in NK cells in various types of hemophagocytic lymphohistiocytosis in a population of Polish children. J Pediatr Hematol Oncol. 2019;41(5):e277–e283.
  • Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH): update 2010. Pediatr Hematol Oncol. 2011;33(1):35–39.
  • Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein Barr virus associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001;19(10):2665–2673.
  • Zeng X, Wei N, et al. Treatment outcomes and prognostic analysis of 61 Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Zhong hua xue ye xue za zhi. 2015;36(6):507–510.